**Figure S1.** Underlying diseases of patients undergoing ^{18}F-FDG PET/CT.


Figure S2. Left ventricular ^{18}F-FDG PET/CT uptake given as mean standardized uptake values (SUV$_{mean}$) in different regions of the myocardium (stratified by MPI normal/abnormal findings). No differences were observed in SUV$_{mean}$ across different regions with respect to perfusion findings.

Table S1. Baseline PET/CT and MPI parameters.

PET/CT and MPI parameters	Total cohort n = 302	No myocardial 18F-FDG uptake n = 109	Diffuse myocardial 18F-FDG uptake n = 77	Focal myocardial 18F-FDG uptake n = 24	Focal on diffuse myocardial 18F-FDG uptake n = 92	p-value
Reversible perfusion defect, n (%)	37 (12.3)	14 (12.8)	6 (7.8)	7 (29.2)	10 (10.9)	0.046
Irreversible perfusion defect, n (%)	60 (19.9)	15 (13.8)	14 (18.2)	12 (50.0)	19 (20.7)	0.001
LVEF (%), mean	58.7 ± 13.2	61.2 ± 10.3	57.7 ± 15.5	51.6 ± 15.9	58.3 ± 12.9	0.012
CACS (Agatston), mean±SD	769.1 ± 1190	830.9 ± 1071.7	869.3 ± 171	823.4 ± 923	602.3 ± 809.8	0.61
Rest heart rate prior to MPI, mean±SD	75.5 ± 15.7	76.2 ± 15.9	76.7 ± 14.4	84.3 ± 22.8	72.1 ± 14.6	0.031
Systolic blood pressure, mean±SD	136.4 ± 22.3	140.6 ± 23.0	136.1 ± 19.5	133.3 ± 9.1	133.1 ± 25.1	0.73
Diastolic blood pressure, mean±SD	77.3 ± 11.2	79.3 ± 9.7	77.1 ± 11.6	69.0 ± 16.4	76.6 ± 11.7	0.49
Indication MPI, n (%) Evaluation prior to surgery Suspected progression of CAD Suspected new onset CAD	186 (61.6) 60 (19.9) 56 (18.5)	76 (69.7) 22 (20.2) 11 (10.1)	43 (55.8) 14 (18.2) 20 (26.0)	10 (41.7) 10 (41.7) 4 (16.7)	57 (62.0) 14 (15.2) 21 (22.8)	0.008
MPI stress test, n (%) Adenosine Dobutamine Bicycle	264 (87.7) 29 (9.6) 7 (2.3)	95 (78.2) 9 (8.3) 5 (4.6)	66 (86.8) 8 (10.5) 1 (1.3)	22 (91.7) 2 (8.3) 0 (0)	81 (88.0) 10 (10.9) 1 (1.1)	0.59
Injected 18F-FDG dose (MBq), mean±SD	330.4 ± 47.8	332.0 ± 48.1	318.9 ± 53.3	347.5 ± 23.0	334.2 ± 45.4	0.051
Injected rest 99mTc SPECT dose (MBq), mean±SD	993.0 ± 148	1004.5 ± 131	966.9 ± 172	1017.0 ± 137	993.9 ± 147.4	0.34
Injected stress 99mTc SPECT dose (MBq), mean±SD	348.5 ± 62.8	347.0 ± 46.5	338.5 ± 58.7	367.4 ± 76.0	353.6 ± 77.1	0.19

Table S2. Predictive value of 18F-FDG myocardial uptake pattern for abnormal MPI findings.

Univariate logistic regression analysis for abnormal myocardial perfusion/function on myocardial perfusion imaging-SPECT (total cohort, n = 302)			
Independent variables	OR	95% CI	p-value
Male sex	2.21	1.29–3.97	0.004
Age	1.009	0.97–1.03	0.45
BMI	1.016	0.99–1.04	0.27
Smoking	1.11	0.68–1.82	0.68
Hypertension	1.063	0.67–1.67	0.79
Dyslipidemia	1.14	0.67–1.95	0.63
Diabetes	1.053	0.58–1.90	0.86
Positive family history	0.997	0.43–2.30	0.99
Glucose level prior to FDG PET	1.17	1.04–1.35	0.032
Resting heart rate	1.00	0.99–1.02	0.53
Injected 18F-FDG dose (MBq)	1.00	0.99–1.00	0.113
No myocardial 18F-FDGuptake	0.52	0.32–0.85	0.01
Diffuse myocardial 18F-FDG uptake	1.01	0.59–1.71	0.97
Focal myocardial 18F-FDG uptake	5.10	2.00–13.3	0.001
Focal on diffuse myocardial 18F-FDG uptake	1.15	0.70–1.89	0.59
Focal spot myocardial 18F-FDG uptake	7.12	1.99–25.63	0.003*

BMI, body mass index; CI, confidence interval; OR, odds ratio.